AI Verdict
REGN has stronger fundamentals based on our AI analysis.
ABBV vs REGN Fundamental Comparison
| Metric | ABBV | REGN |
|---|---|---|
| Revenue | $15.0B | $3.6B |
| Net Income | $695.0M | $727.2M |
| Net Margin | 4.6% | 20.2% |
| ROE | N/A | 2.3% |
| ROA | 0.5% | 1.8% |
| Current Ratio | 0.80x | 3.57x |
| Debt/Equity | N/A | 0.06x |
| EPS | $0.39 | $6.75 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ABBV vs REGN: Frequently Asked Questions
Is ABBV or REGN the better stock in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), REGN has stronger fundamentals. ABBV is graded C (78% confidence) while REGN is graded A (80% confidence). This is not investment advice.
How does ABBV compare to REGN fundamentally?
AbbVie Inc. has ROE of N/A vs REGENERON PHARMACEUTICALS, INC.'s 2.3%. Net margins are 4.6% vs 20.2% respectively.
Which stock pays higher dividends, ABBV or REGN?
ABBV has a dividend yield of N/A or no dividend while REGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ABBV or REGN for long term?
For long-term investing, consider that ABBV has a C grade with 78% confidence, while REGN has a A grade with 80% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ABBV vs REGN?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ABBV vs REGN, the AI consensus favors REGN based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.